Epidemiology of Metastatic Castration-Resistant Prostate Cancer in Veterans Nationwide
Journal of the National Comprehensive Cancer Network · 2025
DOI: 10.6004/jnccn.2025.7032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2025. Verfasst von Danielle Candelieri-Surette und 8 weiteren Autor:innen. Beteiligte Einrichtung: 1University of Massachusetts Lowell, Lowell, MA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Veterans. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
Background
There is limited research on the burden and outcomes of patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC), which may result in limited understanding of the disease and lead to suboptimal disease management. Using a validated algorithm to identify mCRPC disease onset, this study offers the first comprehensive description of mCRPC among veterans nationwide.
Methods
The study used data from the Veterans Health Administration’s Corporate Data Warehouse. Participants were identified using the Prostate Datacore, which uses structured data and natural language processing to identify veterans with prostate cancer, metastatic prostate cancer, and mCRPC. We calculated prevalence and age-adjusted incidence rates of mCRPC from 2005 to 2022 and performed Mann-Kendall trend tests to analyze statistical trends within the time series data. We performed a time-to-event analysis to calculate the median time to mCRPC by disease course, as well as a survival analysis from the date of mCRPC diagnosis to death.
Results
We identified 44,246 patients with mCRPC. Prevalence, incidence, and survival increased each year, with the highest prevalence in the western United States. In 2022, the age-adjusted incidence rate was 5 per 1,000 prostate cancer cases. Median time to mCRPC from prostate cancer diagnosis was 5.68 years in patients with de novo disease and 10.98 years in patients with disease progression from localized stages. Median overall survival increased from 1.23 years (95% CI, 1.19–1.27) in 2005 to 2011, to 1.75 years (95% CI, 1.70–1.80) in 2012 to 2017, to 2.17 years (95% CI, 2.11–2.22) in 2018 to 2024, and with differences observed across age groups ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- 1University of Massachusetts Lowell, Lowell, MA.
- 2VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT.
- 3Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT.
- 4Center for Healthcare Organization and Implementation Research, VA Bedford Healthcare System, Bedford, MA.
- 5New England Geriatric Research Education and Clinical Center, VA Bedford Healthcare System, Bedford, MA.
- 6Medicine Service, St. Louis Veterans Affairs Health Care System, Saint Louis, MO.
Zitieren
APA
Candelieri-Surette, D., Lee, J., Lynch, J. A., Chang, N. N., Nelson, T. J., Teerlink, C. C., Pimentel, C., Schoen, M. W., & Berlowitz, D. (2025). Epidemiology of Metastatic Castration-Resistant Prostate Cancer in Veterans Nationwide. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2025.7032
Vancouver
Candelieri-Surette D, Lee J, Lynch JA, Chang NN, Nelson TJ, Teerlink CC, et al. Epidemiology of Metastatic Castration-Resistant Prostate Cancer in Veterans Nationwide. Journal of the National Comprehensive Cancer Network. 2025. doi:10.6004/jnccn.2025.7032
BibTeX
@article{CandelieriSurette2025,
author = {Candelieri-Surette, Danielle and Lee, JongSoo and Lynch, Julie A and Chang, Nai-Chung N and Nelson, Tyler J and Teerlink, Craig C and Pimentel, Camilla and Schoen, Martin W and Berlowitz, Dan},
title = {Epidemiology of Metastatic Castration-Resistant Prostate Cancer in Veterans Nationwide},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2025},
doi = {10.6004/jnccn.2025.7032}
}
EUVIMED